Table 9 Impact of resveratrol on the expression of genes in the context of lung cancer
Type of cancer | Dose range | Cell line | Target | Pathway | Function | Refs. |
|---|---|---|---|---|---|---|
In vivo studies | ||||||
Non-Small Cell Lung Cancer (NSCLC) | 30 mg/kg 0–100 μM | H460, H1650, HCC827 | HK2, Caspase-3, PARP, | AKT, ERK1/2, EGFR | RVT via suppressing the PI3K/AKT-HK2 pathway could play a role in the clinical prevention and treatment of NSCLC | [47] |
In vitro studies | ||||||
NSCLC | 25–200 μM | H1703, H1975 | XRCC1 | AKT, ERK1/2 | RVT via downregulating ERK1/2 and AKT-mediated XRCC1 could enhance the chemosensitivity to etoposide in NSCLC cells | [82] |
NSCLC | 200 μM | A549, H1299 | Beclin-1, LC3 II/I, SIRT1, P62, p70S6K | AKT/mTOR, p38-MAPK | RVT by activating p38-MAPK and inhibiting the AKT/mTOR pathway could induce protective autophagy in NSCLC | [83] |
NSCLC | 0–50 μM | A549, HCC-15 | LC3-II, P62, p53, Bax, Bcl-2, Bcl-xl, Caspase-3/8, PUMA, Cytochrome-c | AKT, NF-κB | RVT via suppressing the AKT/NF-κB pathway could sensitize lung cancer cells to TRAIL | [84] |
Small Cell Lung Cancer (SCLC) | 40 μg/mL | H446 | c-Myc, AIF, Bcl-2, Bax, Bcl-xL, Cytochrome-c | PI3K/AKT | RVT via the PI3K/AKT/c-Myc pathway could inhibit viability in SCLC H446 cells | [85] |